Biotechnology
Commented by Armin Schulz on September 18th, 2025 | 07:15 CEST
Novo Nordisk, PanGenomic Health and Pfizer - Who are the winners of the digital health revolution?
The disruptive force of the digital health revolution is fundamentally changing the healthcare industry. Artificial intelligence, data-driven therapies, and digital diagnostics are opening up billion-dollar markets and catapulting agile players to the forefront. These pioneers are setting new standards in patient-centered care and generating exponential growth in the process. This ecosystem opens up unique opportunities for strategic investors. Today, we take a look at Novo Nordisk's restructuring, PanGenomic Health's AI-driven innovations, and the political uncertainties at Pfizer.
Read
Commented by Fabian Lorenz on September 18th, 2025 | 07:10 CEST
MAJOR DEVELOPMENTS for megatrend stocks: Rheinmetall, BioNTech, First Hydrogen
Rheinmetall is going full throttle: on land, at sea, in the air, and even in space. Its latest bombshell is the announced takeover of Lürssen's naval division. Will this provide the tailwind the stock needs to break through the EUR 2,000 mark on a sustained basis? Analysts view the transaction positively, though some cautionary voices remain. Meanwhile, a major development in Canada is boosting sentiment around First Hydrogen. North Americans aim to be at the forefront of the small modular reactors (SMRs) movement. The potential is enormous. BioNTech also holds significant promise in the fight against cancer. However, challenges have emerged - ironically in the world's largest pharma market. The US government plans to cut or even stop funding for new mRNA vaccine development. BioNTech shares reacted accordingly and may break through their sideways trend downwards.
Read
Commented by Nico Popp on September 18th, 2025 | 07:05 CEST
Understanding metabolism, generating returns: Vidac Pharma, Roche, AstraZeneca
In the search for new treatments against diseases, researchers agree on one thing: the holy grail is unlikely to be found. Instead, it is incremental improvements and combination therapies that promise progress in complex diseases such as cancer. Cell metabolism is considered a promising approach, for example, in cancer, when the metabolism of a cancer cell is disrupted, the cell dies. In this article, we present current approaches and also discuss a biotechnology company that is wholly dedicated to cellular metabolism.
Read
Commented by Carsten Mainitz on September 17th, 2025 | 07:20 CEST
Globex Mining, Deutz, Novo Nordisk – Prices are rising!
On the stock market, there is often a difference between price and value. Companies with strong assets and holdings, or those with business models that benefit from long-term trends, tend to deliver attractive returns for investors in the long run. All the better if such companies can be acquired at a favorable price - one that lies below the fair value of their shares.
Read
Commented by Stefan Feulner on September 16th, 2025 | 07:25 CEST
Broadcom, NetraMark, Adobe – The AI wave continues to roll inexorably forward
Artificial intelligence is more than just hype; it is becoming the central driver of innovation in our time. Whether in industry, medicine, mobility, or finance, this technology is changing processes, increasing efficiency and creating new business models in almost all sectors. Companies that embrace AI early on secure clear competitive advantages. At the same time, a future market with enormous potential is opening up for investors. However, despite the rosy outlook, stock picking is also required here, as many companies are significantly overvalued.
Read
Commented by Fabian Lorenz on September 16th, 2025 | 07:00 CEST
Hot Stock shakes up Big Pharma! BioNxt Solutions aims to replace Ozempic weight loss injection!
BioNxt is currently shaking up Big Pharma. The announcement that it plans to replace the Ozempic weight loss injection with an oral dissolvable film is once again fueling speculation about the share price. Just like in the multiple sclerosis space, the Company aims to disrupt a billion-dollar obesity market. Further exciting operational news is expected in the coming months. Key patents are already in place. With a market capitalization of around CAD 100 million, the Canadian-German life sciences company is far from expensive – even for Big Pharma. The major corporations will undoubtedly be watching BioNxt's development very closely in the coming months. Until then, the stock is likely to trade significantly higher.
Read
Commented by Nico Popp on September 15th, 2025 | 07:15 CEST
No more diet injections! Innovations in weight loss drugs: BioNxt Solutions, Merck & Co., Novo Nordisk
As recently reported by the United Nations Children's Fund (UNICEF), for the first time, more children worldwide are obese than underweight. While this is a great success in the fight against hunger, it also poses new risks. Severe overweight in childhood leads to obesity and associated diseases in adulthood, such as cardiovascular problems and diabetes. The treatment of overweight and diabetes in children is therefore likely to play an even more significant role in the future. GLP-1 receptor agonists have been popular for several years now in the form of modern weight loss injections. With patents expiring soon, experts anticipate substantial further growth and development in this rapidly expanding market. We explain who could benefit and what the future holds for modern diet medications.
Read
Commented by Fabian Lorenz on September 12th, 2025 | 07:15 CEST
200% shares Steyr Motors and PanGenomic Health! When will cancer-fighter BioNTech explode?
More than 200% price gains are not enough: Steyr Motors and PanGenomic Health continue to go full throttle. Despite its strong performance in recent weeks, PanGenomic still appears undervalued. With the use of artificial intelligence, the Canadians want to tap into the billion-dollar market for personalized alternative medicine and dietary supplements in North America. Their e-commerce platform has just gone live. Steyr Motors reports several successes in China, opening up a billion-dollar market for the Austrians. In contrast, BioNTech shares are not moving. Yet the Mainz-based company is increasingly becoming a real cancer fighter. Will the stock soon explode?
Read
Commented by Armin Schulz on September 12th, 2025 | 07:05 CEST
Investing in the future of medicine: A look at Novo Nordisk, NetraMark Holdings and Evotec
AI is completely transforming the pharmaceutical industry. Modern algorithms sift through vast amounts of data, identify promising therapeutic approaches, and advance drug development at record speed. This increase in efficiency is an absolute game changer. Not only does it save billions, but it also significantly increases success rates and catapults agile companies to the forefront. While cumbersome large corporations laboriously digitize their research departments, disruptive start-ups with innovative AI platforms are shaking up the market. It is precisely this dynamic that presents unique opportunities for investors, if they know how to decipher them. Today, we take a closer look at Danish pharmaceutical giant Novo Nordisk, AI specialist NetraMark Holdings, and German research service provider Evotec.
Read
Commented by Armin Schulz on September 11th, 2025 | 07:10 CEST
Forget weight loss injections! BioNxt Solutions is unsettling Big Pharma, but could become an important partner
There is a catch with weight loss injections: they are injections. Studies show that adherence to treatment drops dramatically after one year. What if the blockbuster drug could simply be dissolved under the tongue? That is precisely what BioNxt Solutions is working on. With its patented dissolvable film technology, the Canadian-German biotech company not only aims to revolutionize obesity therapy but also make strides in multiple sclerosis treatment. The approach could transform entire markets.
Read